Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 7/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16274988 | 0.98 | CHRM3 (0.63) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL11484706 | 0.91 | CHRM3 (0.58) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL27681368 | 0.89 | CHRM3 (0.74) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL14547351 | 0.86 | CHRM3 (0.67) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL17294651 | 0.84 | CHRM3 (0.60) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| SCHEMBL16303704 | 0.83 | CHRM3 (0.46) | CHRM3LMNACYP2D6HRH1 | |
| SCHEMBL5161390 | 0.82 | CHRM2 (0.59) | CHRM3CHRM2KCNH2LMNACYP2D6 | |
| Hydrochloric Acid SCHEMBL16274819 | 0.82 | CHRM3 (0.45) | CHRM3LMNACYP2D6HRH1 | |
| SCHEMBL20476344 | 0.81 | CHRM3 (0.64) | CHRM3CHRM2KCNH2CYP2D6CHRM1 | |
| Hydrochloric Acid SCHEMBL6588205 | 0.80 | CHRM3 (0.59) | CHRM3CHRM2KCNH2LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018150347-A1 | COMPOUNDS WITH BETA-ADRENERGIC AGONIST AND ANTIMUSCARINIC ACTIVITY | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-08-23 | — | — | WO | claimed |
| JP-62039567-A | — | — | None | — | — | JP | disclosed |
| WO-2018150347-A1 | COMPOUNDS WITH BETA-ADRENERGIC AGONIST AND ANTIMUSCARINIC ACTIVITY | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-08-23 | — | — | WO | disclosed |
| EP-1275645-B1 | LABELED COMPOUNDS FOR MEASURING THE FUNCTION OF THE MUSCARINIC ACETYLCHOLINE NERVOUS SYSTEM | HAMAMATSU PHOTONICS KK (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-6649142-B2 | Labeled compounds for measuring the function of the muscarinic acetylcholine nervous system | HAMAMATSU PHOTONICS K.K. (JP) | 2003-11-18 | — | — | US | disclosed |
| US-20030113261-A1 | Labeled compounds for measuring the function of the muscarinic acetylcholine nervous system | HAMAMATSU PHOTONICS K.K. (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1275645-A1 | LABELED COMPOUNDS FOR MEASURING THE FUNCTION OF THE MUSCARINIC ACETYLCHOLINE NERVOUS SYSTEM | HAMAMATSU PHOTONICS K. K. (JP) | 2003-01-15 | — | — | EP | disclosed |
| JP-S6239567-A | 4-PIPERIDYL BENZILATE | TAIHO YAKUHIN KOGYO KK | 1987-02-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030113261-A1 | Labeled compounds for measuring the function of the muscarinic acetylcholine nervous system | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885KCNH2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.